SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

INCA033989

INCY·INCYTE CORP
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3 (recruiting)
Time to market
Phase 3 enrollment began September 2026. With primary completion estimated for June 2029 and regulatory filing thereafter, potential FDA approval for ET is at least 3-4 years away if Phase 3 succeeds. The MF registrational program is still in planning.
Why 4/10
No hard dated binary catalyst exists within the next ~12 months. The Phase 3 EXCALIBUR-ET2 trial began enrollment in September 2026 and its primary completion is estimated for June 2029. INCA033989 is one of several pipeline assets at Incyte, a diversified biotech with ~$23.6B market cap and multiple approved commercial products (Jakafi, Opzelura, Monjuvi). A breakthrough designation is not a binary catalyst.
Actionable Insight NEUTRAL

INCA033989 has no imminent binary catalyst. The Phase 3 EXCALIBUR-ET2 trial started enrollment in September 2026 with primary completion estimated for mid-2029, and the registrational program for myelofibrosis remains in planning. Near-term share-price moves for INCY will be driven by commercial execution on Jakafi, Opzelura, and other pipeline readouts (povorcitinib, latarcibart) rather than INCA033989-specific news.

Price Chart

Loading chart...

Executive Summary

INCA033989 is a first-in-class monoclonal antibody from Incyte (INCY) that selectively targets mutant calreticulin (mutCALR), a driver mutation in about 25-30% of myeloproliferative neoplasms. It received FDA Breakthrough Therapy designation in December 2025 for essential thrombocythemia (ET) with Type 1 CALR mutations. Promising Phase 1 data presented at EHA 2026 showed 87% hematologic response in ET (70% complete) and meaningful spleen reductions in myelofibrosis. A Phase 3 trial in ET (EXCALIBUR-ET2) began enrolling in September 2026, but primary completion is not expected until 2029, making it a long-duration pipeline asset at a diversified, commercially-established biotech.

How It Works

INCA033989 is a laboratory-made antibody designed to recognize and bind only to a specific mutated form of a protein called calreticulin (CALR) found on the surface of certain blood-cancer cells. About 25-30% of patients with myelofibrosis or essential thrombocythemia have cancer cells carrying this CALR mutation. By latching onto the mutated protein, the antibody blocks the cancer-driving signals that cause abnormal blood-cell growth and platelet production, while leaving healthy cells untouched. It is designed to be a more targeted alternative to current treatments that broadly suppress blood-cell production.

Trial Status

Two Phase 1 trials (NCT05936359, NCT06034002) completed dose escalation and reported positive data at EHA June 2026. A registrational Phase 3 trial EXCALIBUR-ET2 (NCT07623200) versus best available therapy in CALR-mutant ET began enrollment September 8, 2026, targeting 426 patients. A Phase 3 registrational program for myelofibrosis is in planning.

The Two-Sided Case

▲ Bull Case4
First-in-class targeted therapy for CALR-mutant MPNs with no approved direct competitor, addressing a distinct biomarker-defined population (~25-30% of ET/MF patients)
Phase 1 data at EHA 2026 showed 87% hematologic response in ET (70% complete) and meaningful spleen reductions in MF, with rapid median ~2-week time to response
FDA Breakthrough Therapy designation (December 2025) provides expedited development pathway and signals agency interest
Incyte's deep MPN expertise (Jakafi/ruxolitinib franchise) and strong balance sheet ($3.9B cash) support a large Phase 3 program
▼ Bear Case4
Phase 3 data for the lead ET indication is years away (primary completion ~2029), so no near-term binary catalyst to drive stock
The ET and MF markets already have multiple generic and branded treatments (hydroxyurea, anagrelide, interferons, Jakafi, fedratinib, pacritinib) that physicians are familiar with
Phase 1 sample sizes are small; durability, safety profile, and registration-level efficacy remain unproven
Incyte's stock is dominated by Jakafi (47% of Q3 2026 product sales) and Opzelura commercial execution, making INCA033989 a minority pipeline driver in the near term

Upcoming Catalysts

  • Phase 3 EXCALIBUR-ET2 enrollment updates and interim analyses (no dates specified, primary completion ~2029)
  • Initiation of Phase 3 registrational program for myelofibrosis (planning stage, no date set)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

INCYTE CORP 8-K INCY ·Originating report

Sources · 11

Hover a chip for the title
1 investor.incyte.com2 businesswire.com3 curetoday.com4 ashpublications.org5 ashpublications.org6 clinicaltrials.gov7 clinicaltrials.gov8 ashpublications.org9 sec.gov10 stockanalysis.com11 cancer.gov